Table 3.
Patient Characteristics in Metabolomics Analysis
| Fibrosis stage 0 | Fibrosis stage 1 | Fibrosis stage 2 | Fibrosis stage 3 | Fibrosis stage 4 | |
|---|---|---|---|---|---|
| Subjects, n | 12 | 38 | 100 | 42 | 8 |
| Age, y | 53 ± 9 | 49 ± 11 | 50 ± 11 | 51 ± 8 | 59 ± 5 |
| Sex, males/females | 5/7 | 16/22 | 50/50 | 22/20 | 2/6 |
| BMI, kg/m2 | 34 ± 8 | 35 ± 7 | 35 ± 7 | 35 ± 7 | 38 ± 14 |
| Diabetes subjects, n (%) | 2 (17) | 8 (21) | 36 (36) | 23 (55) | 6 (75) |
| Steatosis | 1.5 ± 0.9 | 1.9 ± 0.8 | 1.8 ± 0.8 | 1.8 ± 0.8 | 1.6 ± 0.9 |
| Lobular inflammation | 0.8 ± 0.4 | 1.3 ± 0.6 | 1.4 ± 0.6 | 1.6 ± 0.7 | 1.4 ± 0.5 |
| Portal inflammation | 0.1 ± 0.3 | 0.2 ± 0.4 | 0.4 ± 0.5 | 0.5 ± 0.5 | 1.0 ± 0.0 |
| Ballooning | 0.4 ± 0.5 | 1.1 ± 0.7 | 1.2 ± 0.6 | 1.5 ± 0.6 | 1.5 ± 0.8 |
| NASH activity score | 2.8 ± 1.3 | 4.2 ± 1.5 | 4.5 ± 1.4 | 5.0 ± 1.3 | 4.3 ± 1.6 |
| Glucose, mg/dL | 79 ± 19 | 93 ± 42 | 100 ± 33 | 103 ± 18 | 107 ± 22 |
| Aspartate aminotransferase, IU/L | 34 ± 19 | 62 ± 48 | 71 ± 54 | 74 ± 41 | 67 ± 23 |
| Alanine aminotransferase, IU/L | 48 ± 38 | 85 ± 75 | 92 ± 62 | 88 ± 56 | 73 ± 32 |
| Triglycerides, mg/dL | 237 ± 173 | 151 ± 64 | 184 ± 167 | 208 ± 163 | 164 ± 60 |
| Hemoglobin A1c, % | 5.7 ± 0.6 | 6.2 ± 1.1 | 6.2 ± 1.3 | 6.9 ± 1.6 | 6.8 ± 0.9 |
| Insulin, mIU/L | 17 ± 70 | 18 ± 7 | 27 ± 23 | 22 ± 13 | 60.1 |
NOTE. Patient information pertaining to the Duke cohort. Subjects are shown according to different fibrosis stages, ranging from absent (stage 0) to cirrhosis (stage 4).